肝硬化患者出凝血系统的变化及凝血功能检测的临床意义  

Changes in hemostasis and clinical significance of coagulation function test in patients with liver cirrhosis

作　　者：柴诗琦 陈金军[1] 祁婷婷[1] CHAI Shiqi;CHEN Jinjun;QI Tingting(Hepatology Unit,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学附属南方医院肝病中心,广州510515

出　　处：《临床肝胆病杂志》2021年第12期2928-2931,共4页Journal of Clinical Hepatology

基　　金：国家科技部重大专项(2018ZX10723203,2018ZX10302206);国家自然科学基金(82070650);国家重点研发计划(2017YFC0908100);广东省珠江人才计划(2017BT01S131);广东省省级科技计划项目(2014B020228003,2015B020226004);南方医科大学临床启动计划(2020CR026);南方医科大学临床研究启动计划(LC2019ZD006);南方医院院长基金(2019Z003)。

摘　　要：肝脏功能在人体促凝和抗凝机制中非常重要,肝硬化患者的出凝血系统变化极为复杂,且存在门静脉系统与外周系统相互作用及病因学差异,呈现出血与血栓形成的双重态势。目前临床常用的凝血功能检测均存在一定局限性。对肝硬化患者进行抗凝治疗时应综合考虑原发病因,并结合多种检测手段,以期做出最有利于患者的临床决策。The liver plays an important role in procoagulant and anticoagulant mechanisms in human body.There are complex changes in hemostasis in patients with liver cirrhosis,with the presence of interaction between the portal venous system and the peripheral system and differences in etiology,and such patients have a dual trend of hemorrhage and thrombosis.At present,there are certain limitations in coagulation function tests commonly used in clinical practice.The primary etiology and results of various coagulation tests should be considered before initiation of anticoagulant therapy for patients with liver cirrhosis,so as to make the best clinical decisions for patients.

关 键 词：肝硬化 出血 血液凝固因子 血液凝固试验 

分 类 号：R575.2[医药卫生—消化系统]